Cardiac rehabilitation in a heart-failure patient using customized "cardiac support net" treatment: a case report.
cardiac rehabilitation
cardiac support net
heart failure
physical function
Journal
Nagoya journal of medical science
ISSN: 2186-3326
Titre abrégé: Nagoya J Med Sci
Pays: Japan
ID NLM: 0412011
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
22
05
2022
accepted:
06
09
2022
medline:
1
11
2023
pubmed:
13
10
2023
entrez:
13
10
2023
Statut:
ppublish
Résumé
At our hospital, we are conducting the "Clinical Study of a Patient-Specific Cardiac Support Net for Dilated Cardiomyopathy (jRCTs042180025)", a multi-facility clinical study of a customized cardiac support net (CSN). Here, we describe the cardiac rehabilitation (CR) of a heart failure (HF) patient after CSN treatment. The patient was a 65-year-old man who exhibited dilated cardiomyopathy (DCM) because of left ventricular non-compaction; his New York Heart Association status was class III. In November 2019, he received CSN treatment. The early CR program was adapted for this patient, and his postoperative course was uneventful. Functional measurements showed improved leg-muscle strength (before treatment: 61.4% BW; at discharge: 77.3% BW). During long-term follow-up, the patient's exercise tolerance increased, as shown by 6-minute walk distance (before treatment: 576 m; long-term follow-up: 600 m) and peak oxygen uptake (before treatment: 12.5 mL/kg/min; long-term follow-up: 13.3 mL/kg/min). In the 2 years since discharge, the patient has not been hospitalized for HF. This report is the first to show that the CSN can be used to perform a CR program in a DCM patient without significant functional decline.
Identifiants
pubmed: 37829491
doi: 10.18999/nagjms.85.3.626
pmc: PMC10565582
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
626-634Déclaration de conflit d'intérêts
Dr Toshiaki Akita is employed by iCorNet Co, a venture company of Nagoya University. The other authors have no conflicts of interest to declare.
Références
Circ Heart Fail. 2019 Apr;12(4):e006067
pubmed: 30946600
Clin Med Insights Cardiol. 2018 Jan 03;12:1179546817751438
pubmed: 29326534
Sci Rep. 2022 Jan 7;12(1):50
pubmed: 34997047
J Crit Care. 2015 Aug;30(4):664-72
pubmed: 25987293
Int J Biochem Cell Biol. 2013 Oct;45(10):2257-65
pubmed: 23665153
J Thorac Cardiovasc Surg. 2011 Sep;142(3):569-74, 574.e1
pubmed: 21269649
JAMA Cardiol. 2020 Feb 1;5(2):175-182
pubmed: 31738366
Circ J. 2019 Jun 25;83(7):1546-1552
pubmed: 31189753
J Cardiovasc Dis Res. 2012 Jan;3(1):22-5
pubmed: 22346141
Circ J. 2019 Nov 25;83(12):2394-2398
pubmed: 31708554
Physiotherapy. 2017 Mar;103(1):1-12
pubmed: 27931870
Circulation. 1991 Mar;83(3):778-86
pubmed: 1999029
EuroIntervention. 2021 Jul 20;17(4):e335-e342
pubmed: 33589408
Eur J Cardiothorac Surg. 2005 Sep;28(3):448-53
pubmed: 16111611
Endocr Metab Immune Disord Drug Targets. 2013 Mar;13(1):58-67
pubmed: 23369138
Int J Cardiol. 2010 Apr 30;140(3):260-5
pubmed: 19664831
J Am Coll Cardiol. 2015 Oct 20;66(16):1747-1761
pubmed: 26483097
Eur Heart J. 2013 Feb;34(7):512-9
pubmed: 23178647
Prog Rehabil Med. 2019 Oct 19;4:20190018
pubmed: 32789265
J Thorac Cardiovasc Surg. 2007 Feb;133(2):590
pubmed: 17258617
Skelet Muscle. 2019 Jan 24;9(1):4
pubmed: 30678732
Crit Care. 2013 Feb 28;17(1):207
pubmed: 23672747